Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

NCT04675333 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

172

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: evorpacept
DRUG: pembrolizumab
DRUG: Cisplatin/Carboplatin; 5FU

Sponsor

ALX Oncology Inc.

Collaborators

[object Object]